Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have earned a consensus recommendation of “Buy” from the twenty-three ratings firms that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $106.82.
Several brokerages have recently weighed in on NBIX. Guggenheim began coverage on Neurocrine Biosciences in a report on Tuesday, June 4th. They issued a “neutral” rating and a $88.00 price objective for the company. Royal Bank of Canada assumed coverage on Neurocrine Biosciences in a report on Wednesday, August 7th. They issued an “outperform” rating and a $118.00 price objective for the company. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Zacks Investment Research raised Neurocrine Biosciences from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their target price for the company from $100.00 to $106.00 in a report on Monday, April 22nd.
In related news, insider Haig P. Bozigian sold 1,300 shares of the company’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $80.03, for a total transaction of $104,039.00. Following the transaction, the insider now directly owns 143,276 shares of the company’s stock, valued at $11,466,378.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Haig P. Bozigian sold 17,486 shares of the company’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $80.03, for a total value of $1,399,404.58. Following the transaction, the insider now directly owns 159,462 shares in the company, valued at $12,761,743.86. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 230,683 shares of company stock valued at $21,039,998. 4.30% of the stock is currently owned by company insiders.
Shares of Neurocrine Biosciences stock traded up $2.36 during trading on Tuesday, hitting $97.24. The stock had a trading volume of 391,600 shares, compared to its average volume of 790,919. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.44 and a quick ratio of 7.32. The firm has a market cap of $8.69 billion, a P/E ratio of 442.00, a PEG ratio of 4.94 and a beta of 1.32. The business has a fifty day moving average of $89.35 and a two-hundred day moving average of $84.21. Neurocrine Biosciences has a fifty-two week low of $64.72 and a fifty-two week high of $126.98.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, July 29th. The company reported $0.37 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.13. The business had revenue of $183.58 million during the quarter, compared to analyst estimates of $161.79 million. Neurocrine Biosciences had a return on equity of 0.46% and a net margin of 2.98%. The company’s revenue was up 89.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.07) earnings per share. As a group, research analysts forecast that Neurocrine Biosciences will post 0.8 earnings per share for the current year.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Recommended Story: Bond
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.